Savara (SVRA) Non Operating Income (2010 - 2026)
Savara (SVRA) reported Non Operating Income of $1.7 million for Q1 2026, down 5.01% year-over-year from $1.8 million in Q1 2025, and up 44.21% on a QoQ basis from $1.2 million in Q4 2025.
Savara (SVRA) has 17 years of Non Operating Income data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Non Operating Income fell 5.01% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 33.8% YoY) and the FY2025 annual result came in at $4.7 million, down 35.61% from the prior year.
- Non Operating Income climbed to $1.7 million in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.1 million in Q4 2024 and bottomed at -$254000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $1.2 million (2025), against an average of $1.2 million.
- The widest annual swing landed in 2022, when Non Operating Income sank 228.93%; it then jumped 869.8% in 2023.
- Tracing SVRA's Non Operating Income over 5 years: stood at $575000.0 in 2022, then soared by 166.26% to $1.5 million in 2023, then surged by 39.12% to $2.1 million in 2024, then slumped by 44.46% to $1.2 million in 2025, then jumped by 44.21% to $1.7 million in 2026.
- Per Business Quant, the three latest SVRA Non Operating Income figures stand at $1.7 million (Q1 2026), $1.2 million (Q4 2025), and $694000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 694,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 947,000.00 |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 778,000.00 |
| Mar 31, 2023 | 1.56 Mn |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Jun 30, 2022 | 219,000.00 |
| Mar 31, 2022 | -254,000.00 |
| Dec 31, 2021 | -671,000.00 |
| Sep 30, 2021 | -574,000.00 |
| Jun 30, 2021 | -489,000.00 |
| Mar 31, 2021 | 197,000.00 |
| Dec 31, 2020 | -729,000.00 |
| Sep 30, 2020 | -278,000.00 |
| Jun 30, 2020 | -125,000.00 |
| Mar 31, 2020 | 819,000.00 |
| Dec 31, 2019 | -210,000.00 |
| Sep 30, 2019 | 39,000.00 |
| Jun 30, 2019 | 215,000.00 |
| Mar 31, 2019 | 808,000.00 |
| Dec 31, 2018 | -1.55 Mn |
| Sep 30, 2018 | 224,000.00 |
| Jun 30, 2018 | 313,000.00 |
| Mar 31, 2018 | 703,000.00 |
| Dec 31, 2017 | 4.72 Mn |
| Sep 30, 2017 | -391,000.00 |
| Jun 30, 2017 | -2.63 Mn |
| Mar 31, 2017 | -437,000.00 |
| Dec 31, 2016 | 383,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Jun 30, 2016 | -68,000.00 |
| Mar 31, 2016 | 15,000.00 |
| Dec 31, 2015 | -3.06 Mn |
| Sep 30, 2015 | -15,000.00 |
| Jun 30, 2015 | -1,000.00 |
| Mar 31, 2015 | 4,000.00 |
| Dec 31, 2014 | 22,000.00 |
| Jun 30, 2014 | 33,000.00 |
| Mar 31, 2014 | 453,000.00 |
| Dec 31, 2013 | 335.00 |
| Sep 30, 2013 | -137.00 |
| Jun 30, 2013 | 1,172.00 |
| Mar 31, 2013 | -2,370.00 |
| Dec 31, 2012 | 2,433.00 |
| Sep 30, 2012 | 1,099.00 |
| Jun 30, 2012 | -8,890.00 |
| Mar 31, 2012 | 311.00 |
| Dec 31, 2011 | 56,547.00 |
| Sep 30, 2011 | 6,448.00 |
| Jun 30, 2011 | 3,277.00 |
| Mar 31, 2011 | 5,105.00 |
| Dec 31, 2010 | -450.00 |
| Sep 30, 2010 | -2,019.00 |